^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PDK4 overexpression

i
Other names: PDK4, Pyruvate Dehydrogenase Kinase 4, Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase Isozyme 4, Mitochondrial, Pyruvate Dehydrogenase Kinase, Isoenzyme 4, Pyruvate Dehydrogenase Kinase, Isozyme 4, Pyruvate Dehydrogenase [Lipoamide]] Kinase Isozyme 4, Mitochondrial, Pyruvate Dehydrogenase, Lipoamide, Kinase Isozyme 4, Mitochondrial, Pyruvate Dehydrogenase Kinase Isoform 4, PDHK4
Entrez ID:
Twitter
Trials
9ms
Cell migration inducing hyaluronidase 1 promotes growth and metastasis of papillary thyroid carcinoma. (PubMed, Bioengineered)
Silencing of CEMIP-induced decrease in cell proliferation and metastasis in PTC were restored by over-expression of STAT3. CEMIP functioned as an oncogenic gene in PTC through PDK4-mediated activation of STAT3/AKT/NF-κB pathway.
Journal
|
PDK4 (Pyruvate Dehydrogenase Kinase 4) • RELA (RELA Proto-Oncogene)
|
PDK4 overexpression
over1year
PDK4-mediated metabolic reprogramming is involved in rituximab resistance in DLBCL via affecting the expression of MS4A1/CD20. (PubMed, Cancer Sci)
We identified that pyruvate dehydrogenase kinase 4 (PDK4) is markedly elevated in DLBCL cells derived from both patients and cell lines with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) resistance...Furthermore, loss of PDK4 expression or treatment with the PDK4 inhibitor dichloroacetate was able to significantly increase rituximab-induced cell apoptosis in DLBCL cells...Importantly, by knocking down or overexpressing of PDK4 in DLBCL cells, we demonstrated that PDK4 has a negative regulation effect on MS4A1/CD20 expression. Collectively, this is the first study showing that targeting PDK4 has the potential to overcome rituximab resistance in DLBCL.
Journal • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1) • PDK4 (Pyruvate Dehydrogenase Kinase 4) • MS4A1 (Membrane Spanning 4-Domains A1)
|
CD20 expression • PDK4 overexpression
|
Rituxan (rituximab) • doxorubicin hydrochloride • vincristine • prednisone • dichloroacetate